Sweden
· Delayed Price · Currency is SEK · Price in DKKDanCann Pharma Statistics
Total Valuation
DanCann Pharma has a market cap or net worth of SEK 12.00 million. The enterprise value is 13.10 million.
| Market Cap | 12.00M |
| Enterprise Value | 13.10M |
Important Dates
The next estimated earnings date is Friday, November 29, 2024.
| Earnings Date | Nov 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DanCann Pharma has 1.54 billion shares outstanding. The number of shares has increased by 750.98% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.54B |
| Shares Change (YoY) | +750.98% |
| Shares Change (QoQ) | +623.83% |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 1.69% |
| Float | 1.54B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.43 |
| PB Ratio | 0.95 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.15 |
| EV / Sales | 1.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.63 |
Financial Position
The company has a current ratio of 0.52
| Current Ratio | 0.52 |
| Quick Ratio | 0.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.73 |
Financial Efficiency
Return on equity (ROE) is -178.54% and return on invested capital (ROIC) is -106.08%.
| Return on Equity (ROE) | -178.54% |
| Return on Assets (ROA) | -80.87% |
| Return on Capital (ROIC) | -106.08% |
| Revenue Per Employee | 1.04M |
| Profits Per Employee | -7.50M |
| Employee Count | 12 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.06% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -93.06% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 60.71 |
| Average Volume (20 Days) | 15,850,947 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DanCann Pharma had revenue of SEK 12.52 million and -90.01 million in losses. Loss per share was -0.13.
| Revenue | 12.52M |
| Gross Profit | -2.16M |
| Operating Income | -85.57M |
| Pretax Income | -88.90M |
| Net Income | -90.01M |
| EBITDA | -80.60M |
| EBIT | -85.57M |
| Loss Per Share | -0.13 |
Balance Sheet
| Cash & Cash Equivalents | -1.08M |
| Total Debt | n/a |
| Net Cash | -1.08M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 9.66M |
| Book Value Per Share | 0.01 |
| Working Capital | -10.42M |
Cash Flow
In the last 12 months, operating cash flow was -20.65 million and capital expenditures -10,660, giving a free cash flow of -20.66 million.
| Operating Cash Flow | -20.65M |
| Capital Expenditures | -10,660 |
| Free Cash Flow | -20.66M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | -17.27% |
| Operating Margin | -683.60% |
| Pretax Margin | -710.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -165.09% |
Dividends & Yields
DanCann Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -750.98% |
| Shareholder Yield | -750.98% |
| Earnings Yield | -1,642.66% |
| FCF Yield | -172.21% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DanCann Pharma has an Altman Z-Score of -8.34. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.34 |
| Piotroski F-Score | n/a |